This Phase 3 clinical trial, known as the ATOM study, is investigating whether a drug called tebentafusp can help prevent or delay the return of uveal melanoma in patients who are considered at high risk of their cancer spreading after treatment of the primary tumour.
Tebentafusp is an immunotherapy drug that has already shown benefits in patients with advanced or metastatic uveal melanoma.The study will assess whether giving tebentafusp after primary treatment can improve long-term outcomes and help patients live longer.
Researchers will also use blood tests to look for signs of molecular residual disease (MRD), which may indicate that microscopic cancer cells remain in the body even when scans appear clear.
This is a Phase 3 trial, meaning the treatment has already been through earlier safety testing and is now being studied in a larger group of patients to better understand its effectiveness.
Participants will receive regular monitoring throughout the study, including blood tests, scans, and follow-up assessments to track for any signs of recurrence and to monitor the safety and tolerability of the treatment.